Search research articles
Contact Us
Filters
Showing results (91-100 of 209) with videos related to
Page
of 21
Sort By:
Prostate Cancer and Prostatic Diseases
|
January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Irfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
European Urology Oncology
|
May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Petros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
The Lancet. Oncology
|
August 8, 2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I Rini, Tanya B Dorff, Paul Elson, et al.
European Urology Oncology
|
August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial
Alan H Bryce, Yu Hui Chen, Glenn Liu, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
The Lancet. Oncology
|
October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Page
of 21
Search research articles
Search
Showing results (91-100 of 209) with videos related to
Sort By:
Page
of 21
Prostate Cancer and Prostatic Diseases
|
January 26, 2022
A randomized phase 2 study of bicalutamide with or without metformin for biochemical recurrence in overweight or obese prostate cancer patients (BIMET-1)
Marijo Bilusic, Nicole J Toney, Renee N Donahue, et al.
BMC Cancer
|
July 25, 2024
Epacadostat plus pembrolizumab versus placebo plus pembrolizumab for advanced urothelial carcinoma: results from the randomized phase III ECHO-303/KEYNOTE-698 study
Irfan Cicin, Elizabeth R Plimack, Howard Gurney, et al.
The Lancet. Oncology
|
February 15, 2018
Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial
Michael B Atkins, Elizabeth R Plimack, Igor Puzanov, et al.
European Urology Oncology
|
May 20, 2020
Pembrolizumab as First-line Therapy in Cisplatin-ineligible Advanced Urothelial Cancer (KEYNOTE-052): Outcomes in Older Patients by Age and Performance Status
Petros Grivas, Elizabeth R Plimack, Arjun V Balar, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2018
Phase II Study of Two Weeks on, One Week off Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma
Eric Jonasch, Rebecca S Slack, Daniel M Geynisman, et al.
The Lancet. Oncology
|
August 8, 2016
Active surveillance in metastatic renal-cell carcinoma: a prospective, phase 2 trial
Brian I Rini, Tanya B Dorff, Paul Elson, et al.
European Urology Oncology
|
August 19, 2020
Patterns of Cancer Progression of Metastatic Hormone-sensitive Prostate Cancer in the ECOG3805 CHAARTED Trial
Alan H Bryce, Yu Hui Chen, Glenn Liu, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
The Lancet. Oncology
|
October 3, 2017
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
Arjun V Balar, Daniel Castellano, Peter H O'Donnell, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 30, 2016
The DART Study: Results from the Dose-Escalation and Expansion Cohorts Evaluating the Combination of Dalantercept plus Axitinib in Advanced Renal Cell Carcinoma
Martin H Voss, Rupal S Bhatt, Elizabeth R Plimack, et al.
Page
of 21